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highest rates of 30-day readmission at 23.9%.
Methods: We retrospectively examined all patients dis-
charged from the vascular surgery service at a single university
hospital over 12 months. We also prospectively followed pa-
tients discharged over one month. 2 tests with Bonferroni
correction were used.
Results: 96 (13%) of the 766 patients discharged
from vascular surgery were readmitted within 30 days.
Of the readmissions, 72 (75%) were unplanned; there-
fore, the unplanned readmission rate was 9%. The most
frequent reasons for unplanned readmission were wound
complications (29%), worsening peripheral arterial dis-
ease (PAD) or nonhealing ulcers (23%), electrolyte dis-
turbance/emergent dialysis (8%), and graft occlusion
(6%). One patient died during readmission. In the pro-
spective study, 13% of patients were readmitted; none
were readmitted to an outside hospital. The presence of
diabetes predicted readmission (p  0.001). Patients
undergoing procedures for PAD (12%) and end stage
renal disease (ESRD) (12%) had a higher (p  .03)
readmission rate than those undergoing procedures for
abdominal aortic aneurysm (4%) or carotid stenosis (4%).
Conclusions: Rehospitalization in vascular surgery pa-
tients can be reduced below rates gleaned from interrogation
of Medicare data. Diabetics and patients undergoing proce-
dures for PAD or ESRD are more likely to be readmitted.
Freedom from readmission in vascular surgery patients
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SS19.
Differential Expression of ERK and Akt Following Nitric
Oxide Exposure in Type 1 and Type 2 Diabetic Rats
Zachary Emond, Vinit Varu, Sadaf Ahanchi, Janet Mar-
tinez, Melina R. Kibbe. Vascular Surgery, Northwestern
University, Chicago, ILObjectives: Diabetic patients develop greater reste-
nosis from neointimal hyperplasia after vascular interven-
tions. Previously, we reported that nitric oxide (NO)
decreased neointimal hyperplasia significantly more in
type 2 diabetic rats than controls, but not at all in type 1
diabetic rats. Given the different insulin levels between
these animal models, and that insulin is known to regu-
late ERK and Akt, we hypothesized that NO differen-
tially effects ERK and Akt activity in type 1 vs type 2
diabetic rats.
Methods: To induce type 2 diabetes, Zucker diabetic
fatty (ZDF) rats were fed Purina 5008 chow. To induce type
1 diabetes, lean Zucker (LZ) rats were injected with strepto-
zotocin (STZ; 60mg/kg). Rats with glucose300mg/dL
were included in the study. Non-STZ LZ rats served as
controls. The carotid artery injury model was performed.
Groups included injury and injuryPROLI/NO (20 mg)
[n6/group].At 14days, phosphorylatedERK(pERK) and
Akt (pAkt) expression was assessed by immunofluorescent
staining.
Results: There were no changes in pERK expression
after NO treatment in LZ control and type 1 diabetic rats
but increased expression in type 2 diabetic rats (44%, p 
0.009). This increase was observedmainly in the adventitia.
pAkt expression decreased in the LZ control (47%, p 
0.012) and type 1 diabetic (51%, p  0.043) rats after NO
treatment but increased in type 2 diabetic rats (53%, p 
0.003). These changes occurred mostly in the neointimal
and adventitia. Interestingly, NO increased the pERK/
pAkt ratio by 29% in the LZ control and 47% in the type 1
diabetic rats but decreased the pERK/pAKT ratio by 12%
in the type 2 diabetic rats.
Conclusions: NO differentially effects the expression
of pERK and pAkt in type 1 vs type 2 diabetic rats, by
decreasing the pERK/pAkt ratio in type 2 diabetic but
increasing this ratio in type 1 diabetic and control rats.
These data suggest one mechanism by which NO inhibits
neointimal hyperplasia in hyperinsulinemic environ-
ments.
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Renal Volume and Blood Pressure Response to Renal
Artery Stenting
J. Gregory Modrall, R. James Valentine, Carlos H. Tima-
ran, Eric B. Rosero, Thomas Anthony, G. Patrick Clagett,
Clayton Trimmer. Surgery, University of Texas Southwest-
ern Medical Center, Dallas, TX
Objectives: The ASTRAL Trial disputed the benefit of
renal artery stenting (RAS) when applied to all hypertensive
patients with renal artery stenoses. However, some patients
may benefit from RAS, and the challenge is to uncover
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purpose of the current study was to identify kidney mor-
phological features that predict a favorable blood pressure
(BP) response to RAS.
Methods: The study cohort consisted of 97 patients
who underwent RAS over 9 years. Patients were catego-
rized as “responders” based on modified AHA guide-
lines: Bp  160/90 mm Hg on fewer anti-hypertensive
medications or diastolic Bp  90 mm Hg on the same
medications. Renal volume was estimated as kidney
length x width x depth/2 based on preoperative CTA or
MRA.
Results: The mean age of the cohort was 68 1 years.
A favorable BP response was observed in 33 of 97 patients
(34%). Ipsilateral renal volume was significantly greater for
responders, compared to nonresponders (152 6 vs 132
4 cm3; p  .0049), whereas kidney length, width, and
depth did not discriminate responders from nonre-
sponders. No patient with a renal volume less than 75 cm3
was a BP responder. There was a highly significant associ-
ation between renal volume and response to RAS (Figure;
Chi square for trend; p  .0035).
Conclusions: A larger ipsilateral renal volume por-
tends a greater probability of a favorable BP response to
RAS. Conversely, a renal volume less than 75 cm3 defined
the threshold below which a kidney is unlikely to benefit
from RAS. These data suggest that renal volume should be
considered in patient selection for RAS.
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The Contemporary Management of Splenic Artery An-
eurysms
Ryan O. Lakin, James F. Bena, Timur P. Sarac, Samir Shah,
Leonard P. Krajewski, Sunita D. Srivastava, Daniel G. Clair,
Vikram S. Kashyap. Vascular Surgery, Cleveland Clinic,
Cleveland, OHObjectives: The natural history of splenic artery aneu-
rysms (SAA) is poorly delineated. The objective of this
study was to review our experience with observation and
treatment of SAA.
Methods:Between 1996-2009, 129 patients with SAA
were evaluated. 64 patients underwent open surgical repair
(n 13) or endovascular coil/glue ablation (n 51) while
65 patients underwent serial observation. Statistical analy-
ses and Kaplan-Meier estimates for survival were per-
formed. Mortality was verified via the Social Security data-
base.
Results: Patients (61  11 years, 69% female) were
investigated for abdominal symptoms (50%) or had the
incidental finding of SAA (mean size 23  14 mm).
Seven patients (5.4%) presented with rupture, and were
treated emergently with 2 perioperative mortalities
(29%). Patients requiring SAA treatment were more
likely male (42 vs 20%, p  0.011), younger (58.5 vs
63.8 years, p  0.006), and trended towards current
smoking (16 vs 5%, p  0.07). The mean aneurysm size
was 3.1 cm for the treated group and 1.5 cm for the
observed group (p  0.001). Endovascular repair was
safe and durable with thrombosis or a regression of SAA
size on follow-up CT imaging (mean 1.2 years). The
mean rate of growth for observed SAA was 0.07mm/
year. Ten-year survival was 88.2% (95% CI: 79.8, 97.5)
for all patients (observed group 93.4%, treated group
84.4%, p  0.23). No late aneurysm related mortality
was identified.
Conclusions: Ruptured SAA are lethal. Large SAA can
undergo endovascular ablation safely with durable SAA
regression. Smaller SAA (2 cm) grow slowly and carry a
negligible rupture risk.
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